tiprankstipranks
Krystal Biotech reports Q4 EPS ($1.25), consensus ($1.32)
The Fly

Krystal Biotech reports Q4 EPS ($1.25), consensus ($1.32)

"In 2022, we were focused on advancing B-VEC toward approval and getting commercially prepared for a potential launch this year, and I thank the entire Krystal team for their dedication and perseverance in helping us achieve our objectives," said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc. He added, "Our focus in 2023 will be on advancing our pipeline and demonstrating the breadth of our gene delivery platform. We plan to have ASTRA, our second manufacturing facility, operational early this year which will enable us to advance our pipeline products in a timely manner."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on KRYS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles